| 0 (0%) | 09-27 14:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.71 |
1-year : | 4.33 |
| Resists | First : | 3.18 |
Second : | 3.71 |
| Pivot price | 2.65 |
|||
| Supports | First : | 2.6 |
Second : | 2.25 |
| MAs | MA(5) : | 2.7 |
MA(20) : | 2.65 |
| MA(100) : | 2.19 |
MA(250) : | 3.01 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 69.9 |
D(3) : | 49.8 |
| RSI | RSI(14): 67.8 |
|||
| 52-week | High : | 5 | Low : | 1.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CLGN ] has closed It is unclear right now based on current values. 47.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.18 - 3.2 | 3.2 - 3.21 |
| Low: | 2.69 - 2.7 | 2.7 - 2.71 |
| Close: | 3.12 - 3.14 | 3.14 - 3.16 |
Sat, 27 Sep 2025
What drives CLGN stock price - Stock Liquidity Analysis & Outstanding Profit Strategies - Early Times
Mon, 15 Sep 2025
Revolutionary Tendon Healing Matrix: CollPlant Expands VergenixSTR Distribution Across Europe with Polish Deal - Stock Titan
Mon, 15 Sep 2025
CollPlant Expands the Distribution of its VergenixSTR Product in Europe - Nasdaq
Mon, 15 Sep 2025
CollPlant Expands VergenixSTR Distribution in Europe - MSN
Mon, 25 Aug 2025
Leading Regenerative Medicine Firm CollPlant to Present Latest rhCollagen Innovations at Global Conference - Stock Titan
Tue, 19 Aug 2025
Earnings To Watch: CollPlant Biotechnologies Ltd (CLGN) Reports Q2 2025 Result - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 8.91e+006 (%) |
| Held by Institutions | 10.1 (%) |
| Shares Short | 108 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.237e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 775.4 % |
| Return on Equity (ttm) | -38 % |
| Qtrly Rev. Growth | 2.4e+006 % |
| Gross Profit (p.s.) | -34.7 |
| Sales Per Share | -96.61 |
| EBITDA (p.s.) | 1.82716e+006 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 2.59 |
| Dividend | 0 |
| Forward Dividend | 41630 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|